Format

Send to

Choose Destination
ACS Chem Biol. 2018 Jan 19;13(1):60-65. doi: 10.1021/acschembio.7b00870. Epub 2017 Dec 5.

ToP-DNJ, a Selective Inhibitor of Endoplasmic Reticulum α-Glucosidase II Exhibiting Antiflaviviral Activity.

Author information

1
Department of Biochemistry, University of Oxford , South Parks Road, Oxford OX1 3QU, U.K.
2
Department of Hospital Pharmacy, University of Toyama , 2630 Sugitani, Toyama 930-0194, Japan.

Abstract

Iminosugars have therapeutic potential against a range of diseases, due to their efficacy as glycosidase inhibitors. A major challenge in the development of iminosugar drugs lies in making a compound that is selective for the glycosidase associated with a given disease. We report the synthesis of ToP-DNJ, an antiviral iminosugar-tocopherol conjugate. Tocopherol was incorporated into the design of the iminosugar in order to direct the drug to the liver and immune cells, specific tissues of interest for antiviral therapy. ToP-DNJ inhibits ER α-glucosidase II at low micromolar concentrations and selectively accumulates in the liver in vivo. In cellular assays, the drug showed efficacy exclusively in immune cells of the myeloid lineage. Taken together, these data demonstrate that inclusion of a native metabolite into an iminosugar provides selectivity with respect to target enzyme, target cell, and target tissue.

PMID:
29161006
PMCID:
PMC5824344
DOI:
10.1021/acschembio.7b00870
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center